Korean J Gynecol Oncol.  2008 Mar;19(1):1-8. 10.3802/kjgo.2008.19.1.1.

Major clinical research advances in gynecologic cancer 2007

• Kim K
• Kim JW
• Kang SB

• KMID: 1979496
• DOI: http://doi.org/10.3802/kjgo.2008.19.1.1

Abstract

Major clinical research advances in gynecologic cancer in 2007 are as follows. Human papillomavirus (HPV) vaccines were shown to be effective in preventing cervical intraepithelial neoplasia (CIN). In treating cervical cancer, the intensity-modulated radiotherapy (IMRT) was suggested to be less toxic than the conventional radiotherapy was. Minimally invasive surgery, especially robot surgery is expected to be more popular in future. Adjuvant radiotherapy did not increase the survival rate in early endometrial cancer. Adjuvant chemoradiation was demonstrated to be superior to adjuvant radiation in the treatment of early endometrial cancer. Hormone therapy in endometrial cancer was effective but has high recurrence rate. Pelvic/abdominal pain, increased abdominal size/bloating, difficulty eating/feeling full, urinary frequency/urgency could be the symptoms of ovarian cancer. Serial CA-125 measurement or combining ultrasonography and CA-125 could be effective screening strategies of ovarian cancer. Molecules interfering vascular-endothelial growth factor (VEGF) were shown to be effective in the treatment of ovarian cancer.

Keyword

Gynecology; Urogenital neoplasms; Biomedical research

MeSH Terms

Cervical Intraepithelial Neoplasia
Endometrial Neoplasms
Female
Gynecology
Humans
Mass Screening
Ovarian Neoplasms
Radiotherapy, Adjuvant
Radiotherapy, Intensity-Modulated
Recurrence
Survival Rate
Urogenital Neoplasms
Uterine Cervical Neoplasms
Vaccines
Vaccines

Reference

1. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007. 356:1915–1927.

2. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007. 369:2161–2170.

3. Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: A randomized trial. JAMA. 2007. 298:743–753.

4. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007. 356:1928–1943.

5. Pedersen C, Petaja T, Strauss G, Rumke HC, Poder A, Richardus JH, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health. 2007. 40:564–571.

6. Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007. 25:4931–4939.

7. Koh WJ. Controversies in the radiotherapeutic management of cervical cancer. J Clin Oncol. 2003. 21:218s–223s.

8. Chen MF, Tseng CJ, Tseng CC, Kuo YC, Yu CY, Chen WC. Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy: Comparison with conventional radiotherapy. Int J Radiat Oncol Biol Phys. 2007. 67:1438–1444.

9. Wertheim E. The extended abdominal operation for carcinoma uteri: Based on 500 operative cases. Am J Obstet Dis Women Children. 1912. 66:169–232.

10. Meigs JV. Wertheim operation for carcinoma of cervix. Am J Obstet Gynecol. 1945. 49:542–553.

11. Zakashansky K, Bradley WH, Nezhat FR. New techniques in radical hysterectomy. Curr Opin Obstet Gynecol. 2008. 20:14–19.

12. Kim YT, Kim SW, Hyung WJ, Lee SJ, Nam EJ, Lee WJ. Robotic radical hysterectomy with pelvic lymphadenectomy for cervical carcinoma: A pilot study. Gynecol Oncol. 2008. 108:312–316.

13. Boggess J. Robotic surgery in gynecologic oncology: Evolution of a new surgical paradigm. J Robotic Surg. 2007. 1:31–37.

14. Shaeffer DT, Randall ME. Adjuvant radiotherapy in endometrial carcinoma. Oncologist. 2005. 10:623–631.

15. Orton J, Blake B. Adjuvant external beam radiotherapy (EBRT) in the treatment of endometrial cancer: Results of the randomized MRC ASTEC and NCIC CTG EN. 5 trial. J Clin Oncol. 2007. 25:18s. (abstr 5504).

16. Greven K, Winter K, Underhill K, Fontenesci J, Cooper J, Burke T. Final analysis of RTOG 9708: Adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol. 2006. 103:155–159.

17. Hogberg T, Rosenberg P, Kristensen G, de Oliveira C, de Pont Christensen R, Sorbe B, et al. A randomized phase 3 study on adjuvant treatment with radiation (RT) +- chemotherapy (CT) in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991). J Clin Oncol. 2007. 25:18s. (abstr 5503).

18. Gotlieb WH, Beiner ME, Shalmon B, Korach Y, Segal Y, Zmira N, et al. Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer. Obstet Gynecol. 2003. 102:718–725.

19. Kaku T, Yoshikawa H, Tsuda H, Sakamoto A, Fukunaga M, Kuwabara Y, et al. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome. Cancer Lett. 2001. 167:39–48.

20. Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol. 2007. 25:2798–2803.

21. Bankhead CR, Kehoe ST, Austoker J. Symptoms associated with diagnosis of ovarian cancer: A systematic review. BJOG. 2005. 112:857–865.

22. Ryerson AB, Eheman C, Burton J, McCall N, Blackman D, Subramanian S, et al. Symptoms, diagnoses, and time to key diagnostic procedures among older U.S. women with ovarian cancer. Obstet Gynecol. 2007. 109:1053–1061.

23. Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM, et al. Development of an ovarian cancer symptom index: Possibilities for earlier detection. Cancer. 2007. 109:221–227.

24. Neesham D. Ovarian cancer screening. Aust Fam Physician. 2007. 36:126–128.

25. Partridge E, Kreimer A, Buys S, Reding D, Fouad M, Riley T, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial: Results from 4 years of annual screening in a randomized trial. Gynecol Oncol. 2007. 104:2S-35. (abstr 10).

26. Skates S, Drescher C, Isaacs C, Schildkraut J, Armstrong D, Buys S, et al. A prospective multi-center ovarian cancer screening study in women at increased risk. J Clin Oncol. 2007. 25:18s. (abstr 5510).

27. Micha JP, Goldstein BH, Rettenmaier MA, Genesen M, Graham C, Bader K, et al. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer. 2007. 17:771–776.

28. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007. 25:5180–5186.

29. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study. J Clin Oncol. 2007. 25:5165–5171.

30. Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008. 26:76–82.

31. Tew W, Colombo N, Ray-Coquard I, Oza A, del Campo J, Scambia G, et al. VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase 2 study. J Clin Oncol. 2007. 25:18s. (abstr 5508).